Immunoprecise Antibodies Ltd Stock Other OTC
Stocks
CA87588T1030
Pharmaceuticals
| Market Cap | 111M 77.85M 68.14M 62.5M 58.36M 7.41B 112M 751M 292M 3.64B 293M 286M 12.57B | P/E 2026 * |
-7.01x | P/E 2027 * | -8.42x |
|---|---|---|---|---|---|
| Enterprise Value | 111M 77.85M 68.14M 62.5M 58.36M 7.41B 112M 751M 292M 3.64B 293M 286M 12.57B | EV / Sales 2026 * |
6.97x | EV / Sales 2027 * | 5.4x |
| Free-Float |
90.98% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Immunoprecise Antibodies Ltd
| 1 day | -6.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 2018-02-20 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 2025-10-19 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 2018-05-23 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 57 | 2025-07-06 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29% | -23.22% | - | - | 77.98M | |
| +4.73% | +5.50% | +19.45% | -8.94% | 66.56B | |
| -1.93% | +1.13% | +55.67% | +219.58% | 57.64B | |
| +1.07% | +42.10% | +42.10% | +42.10% | 42.24B | |
| +3.45% | +3.54% | -49.20% | -56.09% | 39.09B | |
| +3.04% | +7.01% | +62.26% | -24.13% | 31.91B | |
| +10.01% | +33.49% | +163.41% | -34.35% | 31.65B | |
| +2.68% | +8.68% | +71.42% | +87.73% | 23.35B | |
| +2.87% | +15.37% | +10.72% | +196.62% | 18.92B | |
| -0.13% | +1.91% | +67.83% | +127.66% | 17.17B | |
| Average | +1.95% | +7.39% | +49.30% | +61.13% | 36.5B | |
| Weighted average by Cap. | +2.77% | +6.50% | +44.29% | +54.03% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.88M 11.17M 9.78M 8.97M 8.38M 1.06B 16.13M 108M 41.85M 523M 41.98M 41.07M 1.8B | 20.47M 14.41M 12.61M 11.57M 10.8M 1.37B 20.79M 139M 53.96M 674M 54.13M 52.95M 2.33B |
| Net income | -14.29M -10.06M -8.8M -8.07M -7.54M -958M -14.52M -97.04M -37.67M -471M -37.79M -36.96M -1.62B | -12M -8.45M -7.39M -6.78M -6.33M -804M -12.19M -81.51M -31.64M -395M -31.74M -31.05M -1.36B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
